Prevalence of Apolipoprotein E Phenotypes in Ischemic Cerebrovascular Disease protein that plays a critical role in triglyceride (TG)-rich lipoprotein catabolism and cholesterol homeostasis. The genetic polymorphism of apo E results from the existence of three common codominant alleles (E2, 3, and c4) that code for three apolipoprotein isoforms, E2, E3, and E4. Apo E3 is the predominant isoform. Apo E4 differs from E3 by an amino acid substitution at position 112 (Cys--Arg) and from E2 by a substitution at position 158 (Arg->Cys). Apo E3 acts as a ligand for two receptors: the apo E or "remnant" receptor, which is specifically hepatic, and the low density lipoprotein (LDL) receptor (apo B/E receptor). The catabolism of TG-rich lipoproteins appears to be modulated by the affinity of apo E for apo E or apo B/E receptors. Apo E2 binds defectively to receptors, and this results in an increase in the number of LDL receptors, thereby lowering cholesterol levels. Apo E4 is not covalently bonded to apo A-TI, and its transfer from high density lipoproteins (HDL) to TG-rich lipoproteins is enhanced. This accelerates hepatic remnant captation by apo E receptors and downregulates the number of LDL receptors, thereby enhancing cholesterol levels. Several studies have indicated that among the three most frequent dominant alleles (c2, e3, and E4), e4 is associated with the early development of coronary artery disease and atherosclerosis.' The role of atherosclerosis and serum lipids in the pathogenesis of cerebral infarction is unclear.2 4 Two studies on the genetic polymorphism of apo E showed a high frequency of the E4 gene, along with a low frequency of the e3 gene. 5, 6 However, in one of these studies the population concerned was not described, and in the other the selection of patients was very restrictive. The aim of this study was to compare the prevalence of the three most frequent alleles of apo E in a defined group of patients with ischemic cerebrovascular disease with those in a control group.
Subjects and Methods
The study group Serum lipid and apo B concentrations were not significantly different in patients and control subjects (Table  2) , whereas apo A-I and apo E levels were significantly lower in patients; it is noteworthy that none of these parameters was outside the normal range, and none varied significantly between the five categories of presumed causes of infarction (data not shown). The chemical composition of the VLDL isolated was similar in patients and control subjects ( Table 2) . In previous studies, significant differences between patients and control subjects were found when data for men and women were considered separately.8.9 Here, cholesterol levels were higher in male patients than in male control subjects (5.10+ 1.46 versus 4.41+0.80 mmol/L; p =0.036), as was the ratio of TG (mmol/L) to apo E (mg/L) (male the E3/E2 phenotype was most frequent in the emboligenic heart disease subgroup (18.2%).
The stepwise logistic regression analysis indicated that hypertension (p<0.0001), apo E level (p<0.008), obesity (p<0.041), the apo E phenotype (E3/E3 versus the others) (p<0.05), and diabetes mellitus (p<0.05) were significant and independent predictors of the presence of ischemic cerebrovascular disease (Table 4) .
Discussion
The population studied here offers a good cross section of elderly people exposed to ischemic stroke. The mean age of our sample was 10 years higher than that of the largest groups previously studied.10-13 Because of this, it is overrepresented in women14'15 and, as a result, the significance of obesity as a risk factor is augmented. Given these slight discrepancies and the known difficulties in interrater comparisons among different classifications,15,16 the distribution of clinical data and risk factors in our sample does not appear to differ notably from that in previous studies.
Numerous authors have assessed the relation between carotid artery atherosclerosis and various lipids or lipoproteins. However, the differences in study de- sign make the comparison of data difficult.2 Apo A-I has only been measured in a few studies.3,4,8,9"17 A significant negative association has been found between ischemic cerebrovascular disease and apo A-I levels in a study of 30 patients with familial hypercholesterolemia. The decrease in apo A-I plasma levels in the patients in our study confirms these data, although it was larger than The E3/E3 phenotype was less frequent in our patients than in the control subjects, confirming previously reported data.56 However, in these two studies a higher prevalence of E4 polymorphism was found in patients than in control subjects. This difference between these studies and the present study could be due to patient selection criteria. Indeed, only men without coronary heart disease, vasculitis, diabetes mellitus, and other endocrine, hepatic, and renal diseases were included in one,6 and the population was not described in the other.5 Moreover, no clear relation between apo E polymorphism and plasma lipid levels was found in the larger study,6 contrary to most population studies.'
A stepwise logistic regression analysis was performed to remove possible bias due to unmatched factors and to appreciate the influence of covariables. In addition to the matching variables (age and sex), each of the variables strongly associated with the presence of ischemic cerebrovascular disease was included in the model. Plasma apo B and total cholesterol levels were strongly correlated (r=0.816). The latter parameter was therefore not included in the regression model. Plasma TG levels, which depended on the presence of diabetes, were also excluded. It is noteworthy that apo E plasma levels and the apo E phenotype were the sole significant lipidic predictors of ischemic cerebrovascular disease. However, an age-and sex-matched control group differed significantly from the "normal" population of healthy young blood donors in terms of apo E phenotype frequency. This difference in apo E phenotype frequencies between the control and blood donor groups could be due to an insufficient number of control subjects. Another possible explanation is that the E3/E3 phenotype may act as a protective factor against early vascular morbidity. In other words, the presence of the E2 allele, calculated from phenotype frequencies (healthy blood donors, 7.2%; patients, 6.5%; control subjects, 0.7%), leads to increased morbidity at an age younger than the mean age of our control subjects. This may be due to a potentialization of other vascular risk factors rather than to a direct deleterious effect, as suggested by studies showing an overrepresentation of the E2 isoform associated with lower limb atheromatosis, even in the absence of dyslipidemia.18
